Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Senescent hepatic stellate cells promote liver regeneration through IL-6 and ligands of CXCR2
Naiyuan Cheng, … , Ki-Hyun Kim, Lester F. Lau
Naiyuan Cheng, … , Ki-Hyun Kim, Lester F. Lau
Published June 16, 2022
Citation Information: JCI Insight. 2022;7(14):e158207. https://doi.org/10.1172/jci.insight.158207.
View: Text | PDF
Research Article Hepatology

Senescent hepatic stellate cells promote liver regeneration through IL-6 and ligands of CXCR2

  • Text
  • PDF
Abstract

Senescent cells have long been associated with deleterious effects in aging-related pathologies, although recent studies have uncovered their beneficial roles in certain contexts, such as wound healing. We have found that hepatic stellate cells (HSCs) underwent senescence within 2 days after 2/3 partial hepatectomy (PHx) in young (2–3 months old) mice, and the elimination of these senescent cells by using the senolytic drug ABT263 or by using a genetic mouse model impaired liver regeneration. Senescent HSCs secrete IL-6 and CXCR2 ligands as part of the senescence-associated secretory phenotype, which induces multiple signaling pathways to stimulate liver regeneration. IL-6 activates STAT3, induces Yes-associated protein (YAP) activation through SRC family kinases, and synergizes with CXCL2 to activate ERK1/2 to stimulate hepatocyte proliferation. The administration of either IL-6 or CXCL2 partially restored liver regeneration in mice with senescent cell elimination, and the combination of both fully restored liver weight recovery. Furthermore, the matricellular protein central communication network factor 1 (CCN1, previously called CYR61) was rapidly elevated in response to PHx and induced HSC senescence. Knockin mice expressing a mutant CCN1 unable to bind integrin α6β1 were deficient in senescent cells and liver regeneration after PHx. Thus, HSC senescence, largely induced by CCN1, is a programmed response to PHx and plays a critical role in liver regeneration through signaling pathways activated by IL-6 and ligands of CXCR2.

Authors

Naiyuan Cheng, Ki-Hyun Kim, Lester F. Lau

×

Figure 2

SASP of senescent HSCs induces hepatocyte proliferation.

Options: View larger image (or click on image) Download as PowerPoint
SASP of senescent HSCs induces hepatocyte proliferation.
(A) Primary hep...
(A) Primary hepatocytes isolated from WT male livers were cocultured with HSCs, senescent HSCs (Sen-HSC), and Sen-HSC with anti–IL-6 antibody (5 μg/mL) and/or SB225002 (SB; 1 μM) as indicated for 24 hours, then stained with anti-Ki67 (red). Ki67+ cells were quantified by counting (n = 6). (B) Immunoblots of protein extracts from hepatocytes cocultured with HSCs or Sen-HSCs were probed with antibodies against phosphorylated (p-) YAP (Y357), YAP, p-STAT3 (Y705), STAT3, p-AKT (S473), AKT1, p-ERK1/2 (T202/Y204), ERK1/2, and β-actin. (C) Primary hepatocytes cocultured with HSCs, Sen-HSC, and Sen-HSC with Super-TDU (TDU; 50 nM), WP1066 (WP; 5 μM), and SCH772984 (SCH; 1 μM) as indicated for 24 hours and were stained with anti-Ki67 antibodies. Ki67+ cells were counted (n > 5). (D) Immunoblots of protein extracts from hepatocytes treated with vehicle (PBS) or IL-6 (10 ng/mL) for 24 hours were probed with indicated antibodies. (E) Hepatocytes treated with vehicle, IL-6, and IL-6 with SCH, TDU, and WP as indicated for 24 hours were stained with Ki67 antibodies and Ki67+ cells counted (n = 5). (F) Immunoblots of protein extracts from hepatocytes treated with vehicle or CXCL2 (10 ng/mL) for 24 hours were probed with indicated antibodies and antibodies against p-p38 (T180/Y182) and p38. (G) Hepatocytes were treated with vehicle, CXCL2, MK2206 (MK; 1 μM), SCH, or in combination as indicated for 24 hours and were stained with Ki67 antibodies. Ki67+ cells were counted (n = 5). (H) Immunoblots of protein extracts from vehicle-, IL-6-, CXCL2-, or IL-6+CXCL2-treated hepatocytes for 24 hours were probed with indicated antibodies. (I) Hepatocytes treated with PBS, IL-6, CXCL2, IL-6+CXCL2, or IL-6+CXCL2 together with SCH, TDU, and WP alone and in combination for 24 hours were stained with anti-Ki67 antibodies; Ki67+ cells were counted (n = 4). Scale bar: 50 μm. Data expressed as mean ± SD. *P < 0.033, **P < 0.002, ***P < 0.001, Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts